Postapproval Study Outcomes of Muscular Ventricular Septal Defect Closure With the Amplatzer Muscular VSD Occluder Authors: Athar M. Qureshi, Henri Justino, Carl Owada, Mohammed Numan, Makram Ebeid, Thomas J. Forbes, David Nykanen, Daisuke Kobayashi, Jillian Kolles, Dan Gutfinger, David Balzer Published: 2026 ABSTRACT BACKGROUND:The Amplatzer Muscular Ventricular Septal Defect (VSD) Occluder (Abbott Structural Heart, Plymouth, MN) was approved by the US Food and Drug Administration in 2007. As a condition of approval, a postapproval study was required to further evaluate its safety and effectiveness. This study reports the clinical outcomes from the postapproval study over 5 years of follow-up.METHODS:Patients with complex congenital muscular VSDs at high risk for surgical closure were enrolled between May 2008 and February 2020 in the United States and Canada. The primary effectiveness end points were technical implant success, acute procedure shunt-closure success, and 1-year shunt-closure success. The primary safety end point was the proportion of patients with any serious adverse event within 12 months of the procedure.RESULTS:A total of 92 patients (median age, 2 years; 50 females) were enrolled in the study. Technical implant success was achieved in 93.8% of patients, and acute shunt-closure success was achieved in 78.0%. Successful shunt closure at 1-year was 94.4% and increased to >98% between 2 and 5 years. Within 12 months of the procedure, all-cause serious adverse events occurred in 47 of the 90 (52.2%) patients which included 7 device-related and 23 procedure-related serious adverse events. Between 1 and 5 years, there was 1 additional device- and procedure-related serious adverse event.CONCLUSIONS:This postapproval study demonstrates that transcatheter muscular VSD closure with the Amplatzer Muscular VSD Occluder is a safe and effective therapy for the treatment of complex congenital muscular VSDs in patients who are at high-risk for surgical closure.REGISTRATION:URL: https://www.clinicaltrials.gov; Unique identifier: NCT00647387. WHAT IS KNOWN Transcatheter closure of complex congenital muscular ventricular septal defects in patients at high risk for a surgical closure is a feasible alternative to surgical closure. Transcatheter closure of complex congenital muscular ventricular septal defects in patients at high risk for a surgical closure is a feasible alternative to surgical closure. WHAT THE STUDY ADDS Five-year follow-up data demonstrate that transcatheter closure of complex muscular ventricular septal defects in patients ≥5.2 kg is safe and effective with late complications being very rare. Five-year follow-up data demonstrate that transcatheter closure of complex muscular ventricular septal defects in patients ≥5.2 kg is safe and effective with late complications being very rare. Successful shunt closure was achieved immediately postprocedure in ≈75% of patients which increased at 1 year to 94.4% and to >98% between 2 and 5 years post-procedure. Successful shunt closure was achieved immediately postprocedure in ≈75% of patients which increased at 1 year to 94.4% and to >98% between 2 and 5 years post-procedure. The presence of a moderate to large congenital ventricular septal defect (VSD) requires closure in children with intractable heart failure, failure of growth, or progressive pulmonary vascular disease.1 In the absence of spontaneous VSD closure, the primary treatment option has traditionally been surgical VSD closure.2,3 However, in children with complex moderate to large VSDs who may be at high risk for a standard surgical closure due to anatomic factors or the overall medical condition, transcatheter VSD closure has acutely been shown to provide a safe and effective alternative to surgical closure.3,4 The Amplatzer Muscular VSD Occluder (Abbott Structural Heart, Plymouth, MN) received Food and Drug Administration approval in 2007 for transcatheter closure of a complex muscular VSD based on the review of 41 patients who were considered high risk for a standard transatrial or transarterial surgical VSD closure.4,5 As a condition of approval, the Food and Drug Administration required a 5-year postapproval study (PAS) to further evaluate the safety and effectiveness of the Amplatzer Muscular VSD Occluder. The clinical outcomes from the PAS over 5 years of follow-up are reported herein. Methods The data and materials used to conduct this research study will not be made publicly available. Study Design The Closure of Muscular VSDs with the Amplatzer Muscular VSD Occluder PAS (ClinicalTrials.gov identifier: NCT00647387) was a single-arm, observational, multicenter, postmarket clinical investigation designed to characterize the safety and effectiveness of the Amplatzer Muscular VSD Occluder in patients ≥5.2 kg. This weight cutoff corresponds to the lower weight limit specified in the Food and Drug Administration approved Instructions for Use which was determined based on the analysis of premarket study data, where a higher rate of major complications was observed in patients weighing <5.2 kg. The study was approved by the institutional review boards of each participating clinical investigational site, and informed written consent was obtained from each patient or legally authorized representative before study participation. Patient Population Enrollment criteria included patients with complex congenital muscular VSDs of significant size to warrant closure and at high risk for a standard transatrial or transarterial surgical VSD closure based on anatomic factors or the overall medical condition. Specific criteria to warrant VSD closure included VSDs with any of the following: (1) a large-volume left-to-right shunt (pulmonary-to-systemic blood flow ratio > 2:1); (2) pulmonary hypertension (pulmonary artery pressure >50% systemic); or (3) clinical symptoms of congestive heart failure. Patients with a history of pulmonary artery banding with a VSD that, in the opinion of the treating investigator, warranted closure were also eligible for enrollment. Anatomic factors that were considered high risk for a standard surgical closure included a muscular VSD with a location requiring an extensive right ventriculotomy or a left ventriculotomy for surgical repair; a muscular VSD that had a failed surgical repair; the presence of multiple apical and anterior muscular VSDs (Swiss cheese septum); and a posterior apical muscular VSD covered by trabeculae. The VSD pattern for each patient was characterized as being a single VSD, multiple VSDs, or a Swiss cheese septum by the study investigator at each clinical site. Patients with either multiple VSDs or a Swiss cheese septum were analyzed as 1 group when comparisons were made with the group of patients with a single VSD. Patients with severe elevation of pulmonary vascular resistance (>7 Wood units), right-to-left shunting (not associated with a tight pulmonary artery band), and irreversible pulmonary vascular disease were excluded from the study. Patients requiring closure of a perimembranous VSD or a postmyocardial infarction VSD, or VSDs with a distance <4 mm from the semilunar (aortic and pulmonary) or atrioventricular valves (mitral and tricuspid), were also excluded. Other exclusion criteria were patients with active infection and those who were unable to take anti-platelet therapy. Patient Enrollment Enrollment into the study was initially prospective before VSD closure. However, due to slow enrollment, retrospective enrollment was allowed beginning in 2016. Once retrospective enrollment began, all patients at each clinical site were screened for enrollment if they met the eligibility criteria, which included the potential to provide a minimum of baseline, procedure, 1-year, and 5-year echocardiography imaging. To mitigate bias, retrospectively enrolled patients were excluded from the technical success end point analysis. Study End Points The primary effectiveness end points were technical success (defined as a device successfully implanted in the VSD), acute procedure success (defined as a defect with ≤2 mm residual shunt at the conclusion of the procedure through/around the muscular VSDs that underwent device occlusion, excluding additional VSDs that were not closed), and shunt closure success (defined as residual shunt ≤2 mm at the 1-year follow-up visit, as assessed by an independent centralized Echocardiography Board). The primary safety end point was the proportion of patients with any serious adverse event (SAE) within 12 months of the procedure. For this study, all SAEs were included in the primary safety end point regardless of cause, which included device-related, procedure-related, and unrelated SAEs. Patient Follow-Up Patient follow-up occurred before hospital discharge and at 30 days, 6 months, 1 year and annually through 5 years post-implant. At each follow-up, the residual shunt was assessed using a transthoracic echocardiogram. The baseline and 1-year echocardiograms were reviewed by an independent centralized echocardiography board. All SAEs were adjudicated by an independent centralized clinical events committee. Device The Amplatzer Muscular VSD Occluder is a self-expanding nitinol wire mesh device consisting of 2 flat symmetrical discs that are linked together by a central cylindrical waist with a diameter intended to correspond to the size of the VSD.4 The device is available in 8 different waist diameters ranging from 4 to 18 mm in increments of 2 mm. The left and right disc diameters for the 4-mm device are 9 mm, and for the remaining device sizes are 8 mm larger than the waist diameter. All 8 device sizes have a uniform waist length of 7 mm. To improve closure, the discs and waist are filled with polyester patches, which are sewn securely within the device with polyester thread. Radiopaque marker bands located at the center of the right and left discs provide visualization of the device under fluoroscopy. The device size (waist diameter) is selected to be up to 2 mm larger than the largest VSD diameter, as assessed by transesophageal echocardiography or angiography at end-diastole. The device may be implanted using either an antegrade or retrograde approach using a 5F to 9F delivery sheath depending on the device size.4,5 Statistical Methods This is a single-arm descriptive study. Categorical data are reported as a count and percentage. Continuous data are reported as mean±SD or as a median with interquartile range. The range may also be provided within square brackets to present the minimum and maximum values. Patient survival was analyzed using the Kaplan-Meier method. Patients with a death or unknown survival status were censored at the last known date reported alive. Data were analyzed using SAS software, version 9.4 (Chicago, IL). Results Study Cohort The study enrolled 92 patients at 28 clinical sites in the United States (N=27) and Canada (N=1) between May 2008 and February 2020. Baseline patient demographics and medical history are shown in Table 1. The median patient age was 2.0 years (interquartile range, 0.8–5.8 years), with 54.3% being female. Approximately one-third of patients were between 3 months and 1 year of age, and ≈50% of patients weighed between 5.2 and 10 kg (Figure 1). Approximately 70% of patients were at high risk for surgical VSD repair due to the overall medical condition, with ≈36% of all patients having a prior pulmonary artery banding procedure and 15% having had a prior surgical closure of a muscular VSD. Patients with a prior pulmonary artery banding were generally recommended to undergo VSD closure combined with de-banding due to the onset of cyanosis. The median patient follow-up was 5.0 years (interquartile range, 4.6–5.4 years), with 96.1% of eligible patients completing the 5-year follow-up (Figure S1). Table 1.Baseline Demographics and Medical History Baseline Demographics and Medical History Baseline demographics. A, Age. B, Weight. VSD Characteristics The VSD characteristics and procedural details are shown in Table 2. Almost half (48.9%) of patients had a single VSD, 34.8% had multiple defects, and 16.3% had a multi-fenestrated Swiss cheese septum. A total of 155 VSDs were identified among 92 patients on the baseline echocardiogram, which included ≈41% apical muscular VSDs, 34% mid-muscular VSDs, 15% anterior muscular VSDs, 5% posterior muscular VSDs, 3% perimembranous VSDs, and 2% inlet VSDs. Seventy-five percent (75%) of the patients had a VSD with a pattern and location that would require an extensive right ventriculotomy or a left ventriculotomy during a surgical VSD repair, as determined at each individual site’s Heart Center. The average measured VSD size was 6.3±2.6 mm (2.0–14.0), and 82.6% of VSDs had a left-to-right shunt. Six patients without pulmonary hypertension had VSDs with a right-to-left shunt at the time of VSD closure associated with the presence of a tight pulmonary artery band. Hemodynamic assessment before VSD closure demonstrated an average pulmonary-to-systemic blood flow ratio of 2.1±1.0 for VSDs with left-to-right shunt (N=76); 1.3±0.5 for VSDs with bidirectional shunt (N=10); and 1.0±0.4 for VSDs with right-to-left shunt (N=6). Table 2.VSD Characteristics and Procedural Details VSD Characteristics and Procedural Details Procedure Outcomes An Amplatzer Muscular VSD Occluder was successfully implanted in muscular VSDs in 94.6% (87/92) of patients overall, and for prospectively enrolled patients (N=80), technical success was achieved in 93.8% (75/80; Table 3). In most cases (N=75; 81.5%) transesophageal echocardiography was used for the implant procedure, while angiography alone was utilized in 10 (10.9%) cases, transthoracic echocardiography alone in 5 (5.4%) cases, and intracardiac echocardiography in 2 (2.2%) cases. Five patients (5.4%) had an unsuccessful implant where a device was not implanted due to interference with the mitral valve (N=1); causing intraprocedural second-degree atrioventricular block requiring device removal (N=2); or due to technical difficulties associated with device recapture necessitating surgical removal or inadvertent device release leading to transcatheter retrieval using a snare (N=2). In another 5 of the 92 patients a second transcatheter procedure was performed to close additional VSDs with the Amplatzer Muscular VSD Occluder such that overall, there were 97 implant procedures performed, with an average procedure time of 226±112 minutes. Within the first 2 years following transcatheter muscular VSD closure with the Amplatzer Muscular VSD Occluder, there were 5 other patients who underwent closure of additional muscular VSDs using a surgical approach in 4 patients and using a perventricular approach in 1 patient (Table 3). Table 3.Procedural and 5-Year Outcomes Procedural and 5-Year Outcomes Transcatheter closure was attempted in 136 muscular VSDs (average of 1.5±1.0 per patient) with an implant success rate of 91.9% (125/136) and an intraprocedural VSD closure rate (defined as a residual shunt ≤2.0 mm) of 78.0% (96/123). The 2 most frequently implanted device sizes were the 6 mm (29.4%) and 8 mm (27.8%) occluders. A single device was implanted in 75% of patients (N=69), and ≥2 devices were implanted in 20% (N=18) of patients. Among the 18 patients implanted with multiple devices, a single procedure was used to implant the devices in 12 patients, and 2 procedures were used to implant the devices in 6 patients. VSD Closure Acute procedural closure success was achieved in 78.0% of patients (71/91), and at 1 year post-implant the shunt closure success increased to 94.4% (68/72). Between 2 and 5 years post-implant shunt closure success further increased and remained consistently >98% (Figure 2). There were no patients in the study who developed hemolysis following VSD closure. Two (2.2%) patients had an additional transcatheter procedure to close a residual shunt through a defect associated with the original implant at 1 and 2.3 years, respectively, following the initial procedure. One patient was treated by adding a second Amplatzer Muscular VSD Occluder into the residual defect, and the second patient was treated by adding a different Amplatzer occluder into the residual defect (Table 3). Echocardiographic residual ventricular septal defect (VSD) shunt assessment. Adverse Events During the first year post-implant SAEs of any cause occurred in 52.2% (47/90) of patients. Overall, there were 153 all-cause SAEs and 23 non-SAEs reported over the 5 years of follow-up. The majority of the SAEs (N=126) were not procedure- or device-related but were submitted for adjudication in accordance with the study protocol. Throughout the study, SAEs occurred in more patients with either multiple VSDs or a Swiss cheese septum (35/47 patients, 74%) compared with patients with a single VSD (16/45 patients, 36%; P<0.001). Patients with multiple VSDs or a Swiss cheese septum tended to undergo VSD closure at a younger age compared with patients with a single VSD (median age at VSD closure of 19.6 versus 27.4 months); and had a history of undergoing more previous cardiac surgery before undergoing VSD closure (72% versus 42%, P=0.003). Procedure-related SAEs occurred in 20 (21.7%) patients, and device-related SAEs occurred in 7 (7.6%) patients as summarized in Table 3. Non-SAEs occurred in 17 (18.5%) patients with none being procedure- or device-related. Intraprocedural hemodynamic instability occurred in 4 patients (weight 5.2–13.4 kg), with a jugular venous approach used in 3 patients and a femoral venous approach in 1 patient. All procedure- and device-related SAEs occurred within 9 days post-implant, except for 1 heart failure SAE that was reported 18 months post-implant in association with a device-related tricuspid regurgitation. Surgical Device Explant A total of 3 patients underwent surgical explant of the device. One patient had an intraprocedural device embolization due to inadvertent entanglement of the left disc within the mitral valve chordae requiring premature device release which was managed with a surgical device explant. The second patient with preexisting diastolic dysfunction had a Swiss cheese ventricular septum and underwent multiple VSD closures using multiple devices (N=6) during 2 separate transcatheter procedures 5 days apart. These resulted in an injury and entrapment of the tricuspid valve that required surgical explant of 2 devices 9 days later, with tricuspid valve repair and surgical closure of 2 VSDs. This patient had a preexisting diagnosis of restrictive cardiomyopathy and a small left ventricle and ultimately underwent orthotopic heart transplantation 9 months later. The third patient with preexisting diastolic dysfunction had multiple apical VSDs and underwent successful transcatheter VSD closure during 2 separate procedures 1 year apart without procedure- or device-related complications. This patient ultimately underwent orthotopic heart transplantation (the native heart was removed with 3 devices within it) due to preexisting restrictive cardiomyopathy with severe left ventricular diastolic dysfunction 18 months following the initial transcatheter VSD closure procedure. Both patients who underwent heart transplantation were found on histopathology of the native heart to have complete tissue coverage of the Amplatzer Muscular VSD Occluders with a neoendothelium and no evidence of a residual defect associated with the occluders. Complete Heart Block There was 1 patient with a Swiss cheese ventricular septum and prior surgery to close a membranous and muscular VSDs who underwent a successful transcatheter closure of a muscular VSD with a single device. This patient developed intraprocedural device-related third-degree heart block with cardiac arrest that required a permanent pacemaker, which was implanted 1 day following VSD closure and had no further device- or procedure-related complications through 5 years of follow-up. Stroke Two strokes were reported in the study. One patient developed a thrombus on the aortic valve on the same day following a successful transcatheter closure of an apical VSD with a single device. The patient subsequently underwent thrombus and pulmonary artery band removal 1 day later, which was complicated by a stroke with left hemiparesis postoperatively. This patient had no further device- or procedure-related complications through 5 years of follow-up. The second patient had a history of an aortic arch repair and underwent a successful transcatheter closure of a mid-to-apical VSD with a single device followed by a planned pulmonary artery band removal and an additional surgical aortic arch repair for residual obstruction. Three days postoperatively the patient developed an ischemic stroke with hemiparesis. Subsequently, the patient had no further device- or procedure-related complications through 5 years of follow-up. Heart Failure There was 1 patient with multiple apical VSDs who underwent successful transcatheter closure of 1 VSD with a single device but had a moderate residual shunt causing ongoing heart failure 5 days post-implant that was successfully managed with pulmonary artery banding and resulted in no residual shunt at 5 years of follow-up. Another patient with a Swiss cheese septum underwent a successful transcatheter closure of an apical VSD with a single device but had severe tricuspid regurgitation and a residual shunt through the remaining VSDs requiring pulmonary artery banding 11 months post-implant. This patient had ongoing heart failure and 6 months later underwent surgical closure of the remaining VSDs through a left ventriculotomy with repair of the tricuspid valve and removal of the device, which apparently entrapped tricuspid valve tissue and caused severe valvular regurgitation. Both of these patients had no further procedure- or device-related complications through 5 years post-implant. Survival The 5-year survival was 97.5%, with 2 patient deaths that occurred ≈2.5 years post-implant, which were unrelated to the procedure or device (Figure 3). One death was due to an intracerebral hemorrhage following an unrelated tricuspid valve-in-valve procedure, and the second death was due to septicemia from an infected indwelling catheter used for total parenteral nutrition in a patient with liver failure. Kaplan-Meier overall 5-year survival. Discussion In this PAS, the Amplatzer Muscular VSD Occluder demonstrated low rates of serious complications and high rates of effective transcatheter VSD closure in patients weighing ≥5.2 kg through 5 years of follow-up. Acute technical implant success was achieved in almost 94% of patients. Residual shunts, though common at the time of implant, resolved over time, with long-term shunt closure documented in >98% of patients at 5 years. Survival at 5 years was 97.5%, with no device- or procedure-related deaths. There was a low rate of device-related SAEs (<8%), with nearly all occurring within 10 days post-implant. The management of newborns with moderate or large VSDs can be complex depending on the presence of associated congenital heart defects, anatomic factors, and overall clinical status.6 Under most circumstances surgical intervention to close the VSD is delayed to allow for spontaneous closure.2,3 However, depending on symptoms and the need to perform other concomitant surgical procedures earlier intervention may be required.1 In symptomatic patients with a large left-to-right VSD shunt who may not be suitable candidates to undergo surgical closure, pulmonary artery banding may be used to temporize symptoms and as a bridge to a more definitive closure procedure while the infant grows.7 In patients without the protection of pulmonary artery banding, careful monitoring of cardiac function and pulmonary vascular resistance is essential to ensure the infant does not progress to having irreversible pulmonary hypertension and Eisenmenger syndrome.8 In children with complex muscular VSDs who may be at high risk for standard surgical closure consideration may be given to utilizing transcatheter VSD closure to avoid potential complications associated with an invasive surgical procedure.1–3 Children with multiple VSDs or a Swiss cheese septum pattern at high risk for undergoing surgical VSD closure may benefit from transcatheter closure using ≥1 devices. Following a successful transcatheter VSD closure, additional interventions may be performed to remove or adjust a previously placed pulmonary artery band, and in some children, it may be necessary to perform additional transcatheter interventions or surgery to close additional VSDs or manage a residual shunt, as demonstrated in this study. In this PAS, ≈50% of patients (47/92) had either multiple VSDs or a Swiss cheese septum, and many patients had either a previous surgical closure of a muscular VSD (15.2%) or pulmonary artery banding (35.9%). Patients enrolled in the study were at high risk for surgical VSD closure based on anatomic factors or the overall medical condition. Transcatheter VSD closure using the Amplatzer Muscular VSD Occluder was successfully performed in >94% (87/92) of patients, with most patients being implanted with a single device (75%). In some patients with multiple VSDs or a Swiss cheese septum, reintervention to close additional VSDs was performed using a transcatheter (N=5), surgical (N=4), or perventricular approach (N=1). From a clinical standpoint, there are some important considerations that may be derived from this long-term follow-up study, given that existing literature on long-term follow-up of VSD closure devices is limited and clouded by data that include a variety of devices and perimembranous VSD closure.9–11 One noteworthy consideration is that nearly all residual shunts (defined as residual flow through the VSD that received a device) disappeared on follow-up. Given the complex nature of many of these defects, immediate residual shunts are common, as was seen in this study. The fact that the data presented here verify that these residual shunts are mostly insignificant, and when present, resolve over time is valuable information for operators performing these procedures and health care providers following these patients. Consistent with the results of this study long-term follow-up studies9–11 demonstrate a high shunt closure rate (95% to 100%) among patients who underwent transcatheter muscular VSD closure using the Amplatzer Muscular VSD Occluder. The Amplatzer Muscular VSD Occluder is implanted within the muscular portion of the interventricular septum, where the device becomes incorporated into the muscular septum and residual shunts may become sealed with device healing and the endothelialization process. Histopathologic examination performed in 2 of the patients from this study who underwent heart transplantation at 9 and 18 months post-implant demonstrated complete tissue coverage of the occluders with a neoendothelium. This finding is consistent with prior studies where it was shown that the majority of the device becomes covered with a neoendothelium within 10 weeks post-implant and completely covered within 7 to 10 months post-implant.12 It is important to note that in both of the patients who underwent heart transplantation, restrictive physiology with diastolic dysfunction was present before muscular VSD device closure and not as a consequence of the implanted muscular VSD occluders. Closure of the muscular VSDs with devices was performed to improve their clinical scenarios, but ultimately heart transplantation was required due to their preexisting restrictive cardiomyopathies. In the long-term follow-up study by Białkowski et al,11 there was 1 patient who underwent successful transcatheter closure of 2 muscular VSDs using 2 separate Amplatzer Muscular VSD Occluders during the second year of life and ultimately underwent orthotopic heart transplantation due to an underlying restrictive cardiomyopathy from endocardial fibrosis 16 years later at the age of 18 years. Consistent with the findings from this study, histopathologic examination 16 years post-implant demonstrated complete neoendothelialization of both devices without any evidence of thrombus formation, inflammatory reaction, or calcification.13 Another consideration based on the results from this study is the low rate of long-term device-related SAEs. Specifically, in long-term follow-up, we observed no cases of device-related cardiac erosion, late occurrence of new valvular damage, or endocarditis from the devices, unlike cardiac implants in other locations.1,14–16 Long-term safety data, as observed in this study and similarly reported in other studies,9–11 are necessary to validate the excellent acute results seen with the Amplatzer Muscular VSD Occluder when comparing to surgical VSD closure techniques. As demonstrated in this study transcatheter muscular VSD closure may be utilized as an alternative to a surgical VSD repair, particularly in patients with multiple prior surgical procedures who may be at high risk for reoperation and those with a favorable VSD location for a transcatheter approach to avoid complications associated with an open cardiac surgical approach. Although several patients in this study who were deemed high risk for a surgical VSD repair ultimately were referred to surgery to undergo closure of additional VSDs or due to complications of heart failure from incomplete VSD closure or device migration, a surgical approach compared with transcatheter closure, is associated with a higher risk for blood loss and transfusion, infection, and a prolonged hospital stay.17,18 In addition, a surgical approach involving a left ventriculotomy may have the potential to result in more arrhythmias, left ventricular dysfunction, and late left aneurysm formation.2,3 In addition to having a lower risk for complications a transcatheter approach for VSD closure may be favored due to offering better access to the VSD within a trabeculated right ventricle, a quicker recovery, and cosmetically to avoid a surgical scar. Thus, a transcatheter approach may have benefits over surgical muscular VSD closure in standard-risk patients as well. Study Limitations Due to the limited number of patients with a complex congenital muscular VSDs at high-risk for surgical closure, enrollment into the study was slow and took almost 12 years to complete. To accelerate study completion retrospective enrollment of patients into the study was allowed beginning in 2016, which resulted in the addition of 12 (13%) patients. Since retrospective enrollment of patients has the potential to bias the interpretation of study results, retrospectively enrolled patients were excluded from the technical success end point analysis; however, all other analyses included all 92 patients. Conclusions Transcatheter closure of complex muscular VSDs in patients ≥5.2 kg using the Amplatzer Muscular VSD Occluder was found based on this study, to be safe and effective, with >94% shunt closure success at 1 year post-implant and a low rate of device-related complications (<8%). The availability of a safe and effective transcatheter treatment option for children with complex muscular VSDs provides an important alternative to surgical VSD closure that should be considered whenever encountering high-risk patients for a standard surgical approach. ARTICLE INFORMATION Disclosures Dr Qureshi: Consultant to Abbott, Medtronic, Inc, W.L. Gore and Associates, and B. Braun. Dr Justino: Consultant to Abbott, Baylis Medtech, Medtronic, and Merit Medical; cofounder of PolyVascular. Dr Ebeid: Consultant, speaker, and proctor to Abbott. Dr Nykanen: Consultant to Abbott, Baylis Meditech, and W.L. Gore and Associates. J. Kolles: Employee of Abbott. Dr Gutfinger: Employee of Abbott. Dr Balzer: Proctor and investigator to Abbott. The other authors report no conflicts. Supplemental Material Figure S1 Supplementary Material